Summary
CYP2C19 inhibitors are compounds that reduce the activity of the CYP2C19 enzyme, which can reduce drug metabolism, potentially impacting the effects of drug therapy.
CYP2C19 is a cytochrome P450 (CYP) enzyme found primarily in the liver that is involved in the metabolism of any medications that are CYP2C19 substrates.[1] CYP2C19 inhibitors can reduce the body’s metabolism of these medications.
The table below outlines some of the most common or clinically relevant CYP2C19 inhibitors.[2][1][3] Importantly, this list is not exhaustive.
| CYP2C19 Inhibitors |
|---|
| Cimetidine |
| Esomeprazole |
| Fluconazole |
| Fluoxetine |
| Fluvoxamine |
| Ketoconazole |
| Loratidine |
| Modafinil |
| Omeprazole |
| Voriconazole |
References
- ^Zanger UM, Schwab MCytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.Pharmacol Ther.(2013-Apr)
- ^Song Y, Li C, Liu G, Liu R, Chen Y, Li W, Cao Z, Zhao B, Lu C, Liu YDrug-Metabolizing Cytochrome P450 Enzymes Have Multifarious Influences on Treatment Outcomes.Clin Pharmacokinet.(2021-May)
- ^Hakkola J, Hukkanen J, Turpeinen M, Pelkonen OInhibition and induction of CYP enzymes in humans: an update.Arch Toxicol.(2020-Nov)